4 Stocks to Watch Trading Under $500M Market Cap
November 23, 2015 11:33 AM
?
Content preferences
Done
NEW YORK, NY / ACCESSWIRE / November 23rd, 2015 / StockMarketLeader.com is an investor alert service that exclusively highlights public companies on the NASDAQ & NYSE with strong upside potential. We are committed to providing the best recommendations in the market on a short and long term basis. Receive our free trade alerts via text message (SMS) and/or email at www.StockMarketLeader.com . Today we are focusing on four companies to watch trading under $500M Market Cap that have been attracting major attention in the market.
KaloBios Pharmaceuticals Inc. (NASDAQ: KBIO), a biopharmaceutical company, develops monoclonal antibody therapeutics for the treatment of cancer in the United States. KaloBios continued higher in pre-market trading on Monday as the short squeeze continues and opened at $22.95. A Martin Shkreli group now controls 70% of the outstanding shares and he was appointed the new CEO on Thursday. Shkreli will be working with the company to continue operations and believes that their drug candidate, Lenzilumab, is a very promising candidate for the treatment of various rare and orphan diseases.
Sign Up Now to Receive Small Cap NASDAQ Alerts With Strong Upside Potential. Free Limited-Time Offer.
Macrocure Ltd. (NASDAQ: MCUR) Macrocure Ltd. is a clinical-stage biotechnology company focused on developing a novel therapeutic platform to address chronic and hard-to-heal wounds, such as diabetic foot ulcers and venous leg ulcers. Macrocure traded 26 times its 3 month average volume on Friday with just over 13 million shares traded and closed up 84.91%. Macrocure gapped 8.16% to an open price of $2.12 on Monday morning with heavy volume continuing.
Want Early Alerts on NASDAQ and NYSE Companies Before They Rally? CLICK HERE .
Can-Fite BioPharma Ltd. (NYSE MKT: CANF) Can-Fite BioPharma Ltd is an advanced clinical stage drug development Company with a platform technology that is designed to address multi-billion dollar markets in the treatment of cancer, inflammatory disease and sexual dysfunction. Can-Fite BioPharma today announced that its drug candidate, CF102, which is currently in Phase 2 trials for hepatocellular carcinoma (HCC), the most common form of liver cancer, will be expanded into treatment for non-alcoholic steatohepatitis (NASH). After closing at $2.64 on Friday, Can-Fite BioPharma opened 37.88% higher on Monday at $3.64 with heavy volume.
To learn more about our NASDAQ Investor Alert Service , CLICK HERE .
SunEdison, Inc. (NYSE: SUNE) SunEdison, Inc. develops, manufactures, and sells silicon wafers to the semiconductor industry. SunEdison, Inc. said on Monday that the chief executives of its two "yieldcos" stepped down, nearly two weeks after the U.S. solar company disclosed it would stop sales of renewable energy assets to such units. As of Friday's close at $2.82, SunEdison's shares lost nearly 62% of their value since November 10th, when SunEdison announced that it would stop sales of renewable energy assets to its "yieldcos." On Monday, SunEdison opened up 7.09% higher at $3.02.
Free NASDAQ Stock Alerts: CLICK HERE To Receive Our Winning NASDAQ & NYSE Stock Alerts For Free.
To Receive Free NASDAQ Alerts, SIGN-UP ON OUR WEBSITE .
About StockMarketLeader.com
StockMarketLeader.com is an investor alert service that exclusively highlights public companies on the NASDAQ & NYSE with strong upside potential. We are committed to providing the best recommendations in the market on a short and long term basis. Receive our free trade alerts via text message (SMS) or email by joining at www.StockMarketLeader.com .
To receive free text message alerts on your phone, compose a new text message to the number 245-87 with the word NASDAQ. For more information visit http://www.StockMarketLeader.com .
Disclosure: Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor's reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. StockMarketLeader.com has not been compensated nor expects to receive any compensation for distribution of our opinions and publicly available information for KBIO, MCUR, SUNE, nor CANF as of 11/23/2015. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. Please visit www.StockMarketLeader.com website, for complete risks and disclosures.
*Gains are calculated by staff and are not guaranteed to be accurate nor a reliable representation. Actual gains may vary. Past gains are not representative of future gains.
SOURCE: StockMarketLeader.com
